$3.71 Billion is the total value of BVF INC/IL's 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $1,239,823,188 | +11.8% | 21,751,284 | 0.0% | 33.43% | +8.1% | ||
AXSM | AXSOME THERAPEUTICS INC | $148,942,579 | -2.7% | 2,131,100 | 0.0% | 4.02% | -5.9% | |
RPTX | REPARE THERAPEUTICS INC | $100,167,215 | +14.2% | 8,291,988 | 0.0% | 2.70% | +10.5% | |
GHRS | GH RESEARCH PLCordinary shares | $93,215,338 | -15.3% | 9,275,158 | 0.0% | 2.51% | -18.0% | |
STRUCTURE THERAPEUTICS INCsponsored ads | $88,235,000 | +21.3% | 1,750,000 | 0.0% | 2.38% | +17.3% | ||
PNT | POINT BIOPHARMA GLOBAL INC | $70,460,199 | -26.4% | 10,563,748 | 0.0% | 1.90% | -28.8% | |
KYMR | KYMERA THERAPEUTICS INC | $65,872,156 | -39.5% | 4,739,004 | 0.0% | 1.78% | -41.5% | |
XENE | XENON PHARMACEUTICALS INC | $62,443,045 | -11.3% | 1,827,958 | 0.0% | 1.68% | -14.2% | |
KURA | KURA ONCOLOGY INC | $61,386,565 | -13.8% | 6,730,983 | 0.0% | 1.66% | -16.6% | |
XOMA | XOMA CORP DEL | $51,199,439 | -25.4% | 3,633,743 | 0.0% | 1.38% | -27.8% | |
FDMT | 4D MOLECULAR THERAPEUTICS IN | $51,014,367 | -29.6% | 4,007,413 | 0.0% | 1.38% | -31.8% | |
TYRA BIOSCIENCES INC | $37,724,223 | -19.1% | 2,739,595 | 0.0% | 1.02% | -21.8% | ||
ZYMEWORKS INC | $37,215,800 | -26.6% | 5,870,000 | 0.0% | 1.00% | -29.0% | ||
REPL | REPLIMUNE GROUP INC | $36,667,346 | -26.3% | 2,143,036 | 0.0% | 0.99% | -28.7% | |
CGEM | CULLINAN ONCOLOGY INC | $28,930,144 | -15.9% | 3,196,701 | 0.0% | 0.78% | -18.7% | |
ETNB | 89BIO INC | $28,504,618 | -18.5% | 1,846,154 | 0.0% | 0.77% | -21.1% | |
THIRD HARMONIC BIO INC | $27,898,312 | +32.8% | 4,365,933 | 0.0% | 0.75% | +28.5% | ||
EPIX | ESSA PHARMA INC | $27,033,264 | +14.4% | 8,748,629 | 0.0% | 0.73% | +10.8% | |
OVID | OVID THERAPEUTICS INC | $26,308,036 | +17.1% | 6,851,051 | 0.0% | 0.71% | +13.3% | |
AN2 THERAPEUTICS INC | $25,148,525 | +89.2% | 1,563,963 | 0.0% | 0.68% | +82.7% | ||
LXRX | LEXICON PHARMACEUTICALS INC | $21,794,912 | -52.4% | 19,995,332 | 0.0% | 0.59% | -53.9% | |
ACIU | AC IMMUNE SA | $21,170,880 | -3.6% | 7,428,379 | 0.0% | 0.57% | -6.7% | |
SLN | SILENCE THERAPEUTICS PLCads | $14,827,729 | +78.7% | 1,508,416 | 0.0% | 0.40% | +73.2% | |
GLYC | GLYCOMIMETICS INC | $14,316,393 | -13.8% | 9,544,262 | 0.0% | 0.39% | -16.6% | |
NEWAMSTERDAM PHARMA COMPANYordinary shares | $14,078,019 | -22.2% | 1,521,948 | 0.0% | 0.38% | -24.6% | ||
IKNA | IKENA ONCOLOGY INC | $13,722,480 | -34.0% | 3,169,164 | 0.0% | 0.37% | -36.1% | |
VERASTEM INC | $13,700,830 | +9.3% | 1,685,219 | 0.0% | 0.37% | +5.7% | ||
CALT | CALLIDITAS THERAPEUTICS ABsponsered ads | $13,695,000 | +16.3% | 750,000 | 0.0% | 0.37% | +12.5% | |
STRO | SUTRO BIOPHARMA INC | $11,617,373 | -25.4% | 3,347,946 | 0.0% | 0.31% | -27.9% | |
VIGIL NEUROSCIENCE INC | $9,775,482 | -42.7% | 1,813,633 | 0.0% | 0.26% | -44.4% | ||
VERV | VERVE THERAPEUTICS INC | $8,619,000 | -29.3% | 650,000 | 0.0% | 0.23% | -31.8% | |
CTMX | CYTOMX THERAPEUTICS INC | $8,508,583 | -25.0% | 6,595,801 | 0.0% | 0.23% | -27.5% | |
TSCAN THERAPEUTICS INC | $7,653,053 | +2.4% | 2,989,474 | 0.0% | 0.21% | -1.0% | ||
JASPER THERAPEUTICS INC | $6,930,000 | -48.9% | 9,900,000 | 0.0% | 0.19% | -50.5% | ||
CDTX | CIDARA THERAPEUTICS INC | $6,464,554 | -16.6% | 6,861,127 | 0.0% | 0.17% | -19.4% | |
PIRS | PIERIS PHARMACEUTICALS INC | $6,141,739 | +80.1% | 20,609,863 | 0.0% | 0.17% | +74.7% | |
ELDN | ELEDON PHARMACEUTICALS INC | $5,927,593 | 0.0% | 4,326,710 | 0.0% | 0.16% | -3.0% | |
NLSP | NLS PHARMACEUTICS LTD | $3,970,689 | -37.2% | 5,747,126 | 0.0% | 0.11% | -39.2% | |
VIRX | VIRACTA THERAPEUTICS INC | $3,759,248 | -26.2% | 3,614,662 | 0.0% | 0.10% | -28.9% | |
RAIN | RAIN ONCOLOGY INC | $3,039,335 | -28.2% | 3,526,729 | 0.0% | 0.08% | -30.5% | |
IVA | INVENTIVA SAads | $2,881,368 | +4.0% | 686,040 | 0.0% | 0.08% | +1.3% | |
CRVS | CORVUS PHARMACEUTICALS INC | $2,001,583 | -36.2% | 1,370,947 | 0.0% | 0.05% | -38.6% | |
ASLAN PHARMACEUTICALS LTDspon ads new | $1,942,498 | -49.3% | 1,049,999 | 0.0% | 0.05% | -51.4% | ||
MOLN | MOLECULAR PARTNERS AGads | $1,768,452 | -34.7% | 443,221 | 0.0% | 0.05% | -36.0% | |
IMUX | IMMUNIC INC | $1,689,655 | -41.4% | 1,149,425 | 0.0% | 0.05% | -42.5% | |
ELEV | ELEVATION ONCOLOGY INC | $1,532,064 | -56.4% | 2,312,200 | 0.0% | 0.04% | -58.2% | |
RZLT | REZOLUTE INC | $251,876 | -33.3% | 190,815 | 0.0% | 0.01% | -36.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
ARQULE INC | 27 | Q4 2019 | 4.8% |
CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-01-29 |
3 | 2024-01-26 |
4 | 2024-01-09 |
4 | 2023-12-20 |
4 | 2023-11-17 |
13F-HR | 2023-11-14 |
3 | 2023-11-13 |
3 | 2023-11-06 |
4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.